1
|
Krul IM, Opstal - van Winden AWJ, Aleman BMP, Janus CPM, van Eggermond AM, de Bruin ML, Hauptmann M, Krol ADG, Schaapveld M, Broeks A, Kooijman KR, Fase S, Lybeert ML, Zijlstra JM, van der Maazen RWM, Kesminiene A, Diallo I, de Vathaire F, Russell NS, van Leeuwen FE. Abstract P2-06-04: Breast cancer after Hodgkin lymphoma: Influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-06-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
After chest radiotherapy (RT) for Hodgkin lymphoma (HL), women experience a dose-dependent increased breast cancer (BC) risk. It is unknown whether endogenous and exogenous gonadal hormones affect the radiation dose-response relationship.
Methods
We conducted a nested case-control study among female 5-year HL survivors treated before 41 years between 1965-2000. Data were collected through medical records and questionnaires for 174 BC cases and 466 matched controls. RT charts, simulation films and mammography reports were used to estimate the radiation dose to the location of the breast tumor.
Results
The median interval between HL and BC diagnosis was 21.9 years. 98% of BC cases had received chest RT, compared to 92% of controls. We observed a linear radiation dose-response curve with an adjusted excess odd ratio (EOR) of 5.4%/Gray (95%CI:1.8%-13.37%). Women with menopause <30 years (caused by high-dose procarbazine or pelvic RT) had a lower BC risk (OR:0.13, 95%CI:0.03-0.54) than women with menopause ≥50 years. BC risk increased with 7.4% for each additional year of intact ovarian function after RT (P<0.001). Among women with an early menopause (<45 years), the use of hormone replacement therapy (HRT) for ≥2 years did not increase BC risk (OR:0.81, 95%CI:0.30-2.21). Endogenous and exogenous hormones did not statistically significantly modify the slope of the radiation dose-response relationship.
Conclusion
HRT use did not appear to increase BC risk in female HL survivors with a therapy-induced early menopause. Moreover, there was no evidence for interaction between RT dose and years with intact ovarian function or HRT use.
Citation Format: Krul IM, Opstal - van Winden AWJ, Aleman BMP, Janus CPM, van Eggermond AM, de Bruin ML, Hauptmann M, Krol ADG, Schaapveld M, Broeks A, Kooijman KR, Fase S, Lybeert ML, Zijlstra JM, van der Maazen RWM, Kesminiene A, Diallo I, de Vathaire F, Russell NS, van Leeuwen FE. Breast cancer after Hodgkin lymphoma: Influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-06-04.
Collapse
Affiliation(s)
- IM Krul
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - AWJ Opstal - van Winden
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - BMP Aleman
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - CPM Janus
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - AM van Eggermond
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - ML de Bruin
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - M Hauptmann
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - ADG Krol
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - M Schaapveld
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - A Broeks
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - KR Kooijman
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - S Fase
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - ML Lybeert
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - JM Zijlstra
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - RWM van der Maazen
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - A Kesminiene
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - I Diallo
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - F de Vathaire
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - NS Russell
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| | - FE van Leeuwen
- Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University MC Cancer Institute, Rotterdam, Netherlands; Utrecht University, Utrecht, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; International Agency for Research on Cancer, Lyon, France; Institut Gustave Roussy, Villejuif, France
| |
Collapse
|